Summary: Roseomonas are described as opportunistic pathogens rarely involved in human infections. Their identification requires molecular methods and their antimicrobial susceptibility pattern varies according to the species. We report the first case of bacteremia due to Roseomonas mucosa in a child with leukemia and reviewed pediatric cases of Roseomonas infection, for which undoubted strain identification was available. Favorable outcome was observed despite resistance to numerous b-lactams that may account for delayed effective treatment, suggesting the low virulence of Roseomonas in children. Here, the strain also displayed unusual resistance to imipenem, highlighting the possible acquisition of additional resistance by this pathogen.
T he genus Roseomonas includes slow-growing nonfermentative gram-negative coccobacilli with pink-pigmented colonies, mostly isolated from environmental samples. 1 Roseomonas are opportunistic pathogens that have rarely been reported in human infections, although an increasing number of cases has been documented in the last decade. Infections mainly consisted of primary or health care-associated bacteremia in immunocompromised adult patients with or without indwelling devices, whereas pediatric cases have been rarely reported. [2] [3] [4] [5] [6] Molecularbased methods were the most accurate to identify the isolates and the antimicrobial susceptibility pattern was variable depending on the species, Roseomonas mucosa being the most resistant one. 6, 7 Here, we report the first case of R. mucosa infection in a child with malignancy and the second imipenem-resistant R. mucosa isolate. A review of pediatric cases including molecular-based identification of the isolates is also presented.
CASE REPORT
A 3-year-old child on maintenance therapy for B-lineage acute lymphoblastic leukemia (ALL) was admitted for febrile aplasia 1 year after ALL diagnosis. The patient had a Broviac catheter for 1 year. Two episodes of febrile aplasia of unknown etiology occurred during hospital stay for intensification therapy in the past year, with a favorable evolution under treatment with piperacillin-tazobactam and amikacin with or without vancomycin. On admission, the patient showed a temperature of 38.51C with a good general condition and clear rhinitis without other particularity. No evidence of inflammation was observed at the catheter insertion site. Laboratory investigation confirmed aplasia diagnosed 2 days before with a white blood cell of 2300/mm 3 and an absolute neutrophil count (ANC) of 385/mm 3 . Increasing C-reactive protein level was noted (from 11.3 mg/L on the day of hospitalization to 50 mg/L on day 2), whereas procalcitonine level remained within normal range (0.28 ng/mL). Urine and 7 BacT/ Alert pediatric blood culture bottles drawn from the Broviac catheter line within a 72-hour period were collected for bacteriological analysis. Two of them were sampled before starting empirical treatment with piperacillin-tazobactam. Five vials were positive for a gram-negative coccobacillus after 2 to 3 days of incubation, and pink, mucoid colonies were observed after 2 to 3 days of subculture. Urines remained negative. In the meantime, the treatment was switched to imipenem and amikacin because of persistent fever despite 4 days of empirical treatment, and the catheter was removed yielding negative cultures. On day 7 of hospitalization, the patient became apyretic, the C-reactive protein level decreased to 28.4 mg/L, and white blood cell count was 7900/ mm 3 with ANC of 2930/mm 3 . The patient was discharged home before availability of antimicrobial susceptibility testing results with an oral treatment with cefixime for 1 week. He had an uneventful follow-up.
Regarding microbiological investigations, 16S rRNA gene sequencing 8 identified R. mucosa (100% sequence identity to R. mucosa, GenBank accession number EU934085), whereas phenotypic identification using API 20NE strips (bioMe´rieux, Marcy l'Etoile, France) misidentified the oxidase-positive isolates as Methylobacterium mesophilicum. Antimicrobial susceptibility testing performed according to standards for nonfermentative gramnegative bacilli 9 revealed resistance to multiple antibiotics including piperacillin-tazobactam, heterogenous resistance to imipenem, and susceptibility to amikacin ( Table 1 ). The hematology-oncology unit displayed a highly controlled environment with terminal filters producing bacteriologically controlled water at the points of use and was controlled semiannually for microbial contamination of air, water, and surfaces. The routine sampling performed before and after the case did not reveal Roseomonas sp. 11 In addition, phenotypic methods were shown inaccurate for both Roseomonas genus identification, several studies reporting misidentification of Roseomonas notably as Methylobacterium, and species identification within the genus (see references 4, 5, 7 and this study). The few studies characterizing collections of Roseomonas spp. identified by 16S rRNA gene sequencing revealed (i) that R. mucosa is the most prevalent species in clinical samples (61% to 90% of the strains), (ii) heterogeneity in antimicrobial susceptibility patterns, R. mucosa being the most resistant species. 6, 7 In children, only few sporadic cases of Roseomonas isolation have been reported, some being incompletely documented or corresponding to transient colonization. [12] [13] [14] In 2006, McLean et al 14 reviewed 7 pediatric cases of catheter-related bacteremia involving Roseomonas gilardii (n = 3), Roseomonas sp. (n = 3), and Roseomonas fauriae (n = 1) identified by phenotypic methods. The case due to R. fauriae should not be considered anymore, as the species is now designed as Azospirillum brasilense. Thus, pediatric cases of Roseomonas infection including undoubted identification of the isolates remain rarely documented and a review of clinical and biological features of the 7 available cases is given in Table 1 . R. mucosa and bacteremia were the most frequently identified species and infection (5 and 4 cases, respectively). Infection mostly occurred in immunocompetent patients. Two bacteremia occurred in patients with central venous catheter (CVC), and in 1 case the bacteremia was related to the catheter. Outcome was favorable in all cases reviewed here (Table 1) or reported by McLean et al 14 whatever the antimicrobial treatment and the removal of the catheter, suggesting low virulence of Roseomonas in children. However, Boyd et al 15 recently reported a case of recurrent peritonitis that induced scarring of the peritoneal cavity leading to peritoneal dialysis precluding.
DISCUSSION
In children with ALL, 3 cases of Roseomonas bacteremia have been previously reported and attributed to an unidentified species (n = 1) 12 and to R. gilardii (n = 2). 12, 13 However, identification should be considered with caution because the isolates have been identified by phenotypic means only and cases have been reported before the R. mucosa characterization in 2003. 7 Common features were the fever upon Roseomonas isolation and the favorable outcome under treatment including an association of ceftazidime and gentamicin or amikacin. The 3 cases occurred in patients with variable ANC (<100, 1330, and 2550/mm 3 , respectively). A CVC with no evidence of inflammation was present in 2 patients and was removed in 1 case yielding negative cultures, as observed here. 13 We report here the first documented R. mucosa bacteremia in a child with malignancy, whereas malignancy is the most common underlying disease in adult patients with R. mucosa bacteremia. 2, 3, [5] [6] [7] 16 Bacteremia, particularly central-line-related bacteremia was commonly described in adults, whereas infrequent in children. 2, 5, 12, 14 The sliminess of the bacterium was thought to favor the catheter colonization. 2 Here, 5 blood cultures sampled through the CVC were positive. However, no peripheral blood cultures were taken and the culture of the catheter remained negative after 72 hours, thereby not allowing to conclude on the CVC-related status of the bacteremia. However, it is noteworthy that the catheter cultivation protocol currently used in routine microbiological laboratory may not be optimal to search for Roseomonas because of slow growth that may exceed the analysis duration. 5 Particular caution should also be taken during the environmental examination in hematology-oncology units to search for slow-growing Roseomonas strains.
R. mucosa showed constant resistance to ampicillin, piperacillin-tazobactam, extended-spectrum cephalosporins (ceftazidime, cefepime) and colistin, frequent resistance to ceftriaxone (68% of the isolates) and trimethoprimsulfamethoxazole (77%) but full susceptibility to aminoglycosides (amikacin, gentamicin) and fluoroquinolones (levofloxacin, ciprofloxacin), and usual susceptibility to ticarcillin-clavulanate (77%) and imipenem (95%). 6, 7 Here, the strain displayed resistance to piperacillin-tazobactam used for empirical treatment and heterogenous resistance to imipenem used as a second-line b-lactam in association with an aminoglycoside. Resistance to imipenem is a rare finding in Roseomonas, which has only been reported in 2 clinical isolates belonging to R. gilardii subsp. rosea and R. mucosa. 7 In the present case, improvement was only observed when effective antimicrobial therapy with amikacin was started and the CVC removed, although we cannot evaluate the relative contribution of each measure to the clinical outcome.
In conclusion, Roseomonas are usually considered as pathogens with low virulence for humans and remain a rare finding in the pediatric population. Here, we reported the first clinically and microbiologically well-documented case of bacteremia due to R. mucosa in a child showing that R. mucosa can be responsible for persistent fever and bacteremia in children with leukemia unless catheter is removed and/or adequate antimicrobial therapy is started. Resistance to b-lactam agents administered in immunocompromised children with bacteremia may result in delayed effective treatment against Roseomonas. It supports the importance of including an aminoglycoside for the treatment of pediatric febrile neutropenia when clinical condition is not improved under b-lactam monotherapy and when gram-negative rods are found by Gram stain examination of blood cultures pending susceptibility testing results.
